Evidence of stage progression in a novel, validated fluorescence-navigated and microsurgical-assisted secondary lymphedema rodent model

• Verfasst von: Will-Marks, Patrick [VerfasserIn]
• Verfasst von: Rafiei, A. [VerfasserIn]
• Verfasst von: Pretze, Marc [VerfasserIn]
• Verfasst von: Gazyakan, Emre [VerfasserIn]
• Verfasst von: Ziegler, Benjamin [VerfasserIn]
• Verfasst von: Kneser, Ulrich [VerfasserIn]
• Verfasst von: Engel, Holger [VerfasserIn]
• Verfasst von: Wängler, Björn [VerfasserIn]
• Verfasst von: Kzhyshkowska, Julia [VerfasserIn]
• Verfasst von: Hirche, Christoph [VerfasserIn]
• Titel: Evidence of stage progression in a novel, validated fluorescence-navigated and microsurgical-assisted secondary lymphedema rodent model
• Verf.angabe: P.A. Will, A. Rafiei, M. Pretze, E. Gazyakan, B. Ziegler, U. Kneser, H. Engel, B. Waengler, J. Kzhyshkowska, C. Hirche
• E-Jahr: 2020
• Jahr: July 23, 2020
• Umfang: 22 S.
• Fussnoten: Gesehen am 19.11.2020
• Titel Quelle: Enthalten in: PLOS ONE
• Ort Quelle: San Francisco, California, US : PLOS, 2006
• Jahr Quelle: 2020
• Band/Heft Quelle: 15(2020,7) Artikel-Nummer e0235965, 22 Seiten
• ISSN Quelle: 1932-6203
• DOI: doi:10.1371/journal.pone.0235965
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: breast-cancer
• Sach-SW: fibrosis
• Sach-SW: inflammation
• Sach-SW: lymphadenectomy
• Sach-SW: lymphography
• Sach-SW: mouse tail
• Sach-SW: node transfer
• Sach-SW: promotes lymphangiogenesis
• Sach-SW: shock-protein 47
• Sach-SW: vegf-c
• K10plus-PPN: 1739140745

Abstract

Secondary lymphedema (SL)is a frequent and devastating complication of modern oncological therapy and filarial infections. A lack of a reliable preclinical model to investigate the underlying mechanism of clinical stage progression has limited the development of new therapeutic strategies. Current first line treatment has shown to be merely symptomatic and relies on lifetime use of compression garments and decongestive physiotherapy. In this study, we present the development of a secondary lymphedema model in 35 rats using pre- and intraoperative fluorescence-guided mapping of the lymphatics and microsurgical induction. In contrast to the few models reported so far, we decided to avoid the use of radiation for lymphedema induction. It turned out, that the model is nearly free of complications and capable of generating a statistically significant limb volume increase by water displacement measurements, sustained for at least 48 days. A translational, accurate lymphatic dysfunction was visualized by a novel VIS-NIR X-ray ICG-Clearance-Capacity imaging technology. For the first-time SL stage progression was validated by characteristic histological alterations, such as subdermal mast cell infiltration, adipose tissue deposition, and fibrosis by increased skin collagen content. Immunofluorescence confocal microscopy analysis suggested that stage progression is related to the presence of a characteristic a SMA(+)/HSP-47(+)/vimentin(+) fibroblast subpopulation phenotype. These findings demonstrate that the in-vivo model is a reliable and clinically relevant SL model for the development of further secondary lymphedema therapeutic strategies and the analysis of the veiled molecular mechanisms of lymphatic dysfunction.